Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

Oral Cancer Clinical Trial

— OMDP  

Official title:

Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02608879
• Other study ID #: 14-00082
• Status: Completed
• Phase: N/A
• Start date: March 2014
• Est. completion date: September 2015

Study information

• Verified date: August 2020
• Source: NYU Langone Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of a novel oral care protocol on the severity and pain of oral mucositis in patients receiving radiation and/or chemotherapy for head and neck cancers. The secondary objectives are to characterize the microbiome associated with oral mucositis, measure salivary proinflammatory cytokines, and evaluate other clinical indicators of the intervention. Participants will be enrolled prior to beginning radiation and/or chemotherapy, and will be randomized to receive either the oral health protocol or standard of care oral hygiene.

Description:

Oral mucositis (OM) is one of the most debilitating adverse effects in cancer patients treated with chemotherapy or radiation (RT). Currently, there are no effective therapies or prevention for mucositis, while several clinical studies have suggested that professional oral care could effectively reduce the severity of Radiation Therapy or chemotherapy-induced oral mucositis. Palliative treatment, rather than preventive or curative measures, remains the standard of care. Evidence-based guidelines do not provide consistent recommendations for the prevention, treatment and management of oral mucositis.

The investigators hypothesize that a monitored regimen of professional oral hygiene prevents harmful ecological shifts in the oral cavity, improve oral health and reduce the duration and severity of Oral Mucositis in cancer patients, consequently improving their overall quality of life during treatment. Moreover, the investigators hypothesize that the weekly oral hygiene regimen performed by an oral health professional is more effective in treating and preventing mucositis than current standard-of-care treatments.

The principal investigator of this project has developed a novel oral care regimen protocol for the treatment of oral mucositis. The "Oral Mucosa Deterging and Periodontal Debridement" (OMDP) protocol consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the debridement of the periodontium and deterging of the oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation. Co-adjuvant treatments such as intense fluoride treatments, oral hygiene instructions and palliative mouth-rinses are also part of the protocol. The hypothesis is that repeated professional prophylaxis of the oral cavity would protect the healthy oral tissue against infection and inflammation often associated with severe cases of mucositis, and consequently reduces mucositis incidence and duration.

Participants in this study would attend approximately 9 study visits over the course of 16-18 weeks, depending on their specific cancer treatment plan. Study participants will be randomized to receive either the oral health protocol, which they will receive on a weekly basis, or standard of care oral hygiene instructions and tooth brushing, preformed on a bi-weekly basis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patient aged 18 years or older;

2. Patients must sign an informed consent before data collection, screening, or initiation of study procedures;

3. Patients who are scheduled to undergo radiation or chemoradiation treatment for head/neck cancer;

4. Patients who have a minimum of 6 natural teeth at the time of enrollment.

Exclusion Criteria:

1. Female patients who are pregnant or lactating at the baseline/screening visit;

2. Patient participating in another biomedical/oral health research study that would interfere with participating in this study;

3. Patient deprived of freedom, under supervision or guardianship;

4. Patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons;

5. Immune compromised or other serious medical conditions, regardless of whether the condition is controlled or not;

6. Patient who requires pre-medication prior to dental treatment;

7. Any patient, in the opinion of the Investigator, who is unable or unlikely to comply fully with the study requirements or procedures for any reason (e.g. major surgical resection of intra-oral structures which would prevent oral care intervention, edentulous, severe periodontal disease, etc).

Related Conditions & MeSH terms

• Mouth Neoplasms
• Mucositis
• Oral Cancer
• Oral Mucositis
• Stomatitis

Intervention

Procedure:
• Oral Mucosa Deterging and Periodontal Debridement (OMDP)
OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
• Standard of Care Oral Hygiene Instructions
Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
• Dental scaling, ultrasonic
An ultrasonic dental scaler will be used to clean the teeth

Other:
• Chlorhexidine
Non-alcoholic chlorhexidine will be used as part of the OMDP protocol

Locations

Country	Name	City	State
United States	NYU Langone Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oral Mucositis Severity - WHO Scale	OM severity will be assessed by the WHO Oral Mucositis Scale at each follow-up visit.; The WHO Oral Mucositis Scale is a 5 point scale (0 to 4) with the following scoring system: 0=None; Soreness with erythema; Erythema, ulcers, can eat solids; Ulcers, liquid diet only; Alimentation not possible	End of Radiation Treatment (approximately week 7)
Primary	Oral Mucositis Severity - NCI Scale	OM severity will be assessed by the NCI-CTCAE Scale (National Cancer Institute - Common Toxicity Criteria and Grading of Adverse Events) at each follow-up visit.; The NCI-CTCAE is a 5 point scale (1-5) with the following grading system: Erythema of the mucosa; Patchy ulcerations or pseudomembranes; Confluent ulcerations or pseudomembranes; bleeding with minor trauma; Tissue necrosis; significant spontaneous bleeding; life-threatening consequences; Death	End of Radiation Treatment (approximately week 7)
Secondary	Level of Oral Pain (FACES Scale)	The FACES Scale is a 6 point scale which ranges from 0-10 (and includes even numbers only). The scale is accompanied by illustrations of faces which represent each score. The subjects is shown the scale and asked to choose the face that best depicts the pain they are experiencing.; 0=No hurt 2=Hurts a little bit 4=Hurts a little more 6=Hurts even more 8=Hurts a whole lot 10-Hurts the worst you could imagine	End of Radiation Treatment (approximately week 7)
Secondary	Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Right Side) From Baseline to Onset of Oral Mucositis	The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.; A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.; For this data, the top five most abundant microbial species are presented.	Baseline to Onset of Oral Mucositis
Secondary	Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Left Side) From Baseline to Onset of Oral Mucositis	The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.; A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.; For this data, the top five most abundant microbial species are presented.	Baseline to Onset of Oral Mucositis
Secondary	Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Right Side) From Baseline to Onset of Oral Mucositis	The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.; A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.; For this data, the top five most abundant microbial species are presented.	Baseline to Onset of Oral Mucositis
Secondary	Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Left Side) From Baseline to Onset of Oral Mucositis	The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area.; A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis.; For this data, the top five most abundant microbial species are presented.	Baseline to Onset of Oral Mucositis
Secondary	Change in the Level of Salivary Proinflammatory Cytokines From Baseline to 16 Weeks	The level of salivary proinflammatory cytokines will be compared between the two groups at each follow-up visit.	Baseline and 16 weeks (final study visit)
Secondary	Change in Quality of Life as Measured by the Composite Score of the EORTC	Quality of life will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) and Head & Neck module (EORTC-H&N) and compared between the two groups at each follow-up visit.; There is not a single composite score for the entire questionnaire, but rather composite scores for each type of assessment (e.g. physical functioning, global health, swallowing, etc.). Possible scores range from 0-100. A lower score indicates low levels of that trait, which a higher score indicates high levels of that trait (e.g. a 100 for "physical functioning" indicates a high level of physical function).	Baseline to the peak of mucositis (approximately week 4)